• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: NEURONETICS, INC. NEUROSTAR ADVANCED THERAPY; TRANSCRANIAL MAGNETIC STIMULATOR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

NEURONETICS, INC. NEUROSTAR ADVANCED THERAPY; TRANSCRANIAL MAGNETIC STIMULATOR Back to Search Results
Model Number NEUROSTAR ADVANCED THERAPY V1.0
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Headache (1880); Memory Loss/Impairment (1958); Nausea (1970); Dizziness (2194); Depression (2361); Lethargy (2560)
Event Date 01/29/2024
Event Type  Injury  
Event Description
A caregiver called into neuronetics to report that after their daughter received a full course of tms, her depressive symptoms worsened significantly and is now bedridden.When speaking with the patient's provider, the patient began to reportedly experience her symptoms following tms including "dizziness, nausea, sensitivity to sound, facial pain, 'zapping' at site of scalp around where coil [was], migraines, memory problems, worsening depression, and has been in bed x2 weeks".
 
Manufacturer Narrative
Neuronetics received a call from a caregiver that reported that after their daughter received tms, her daughter (the patient) experienced a significant worsening of her depression and has been bedridden.The caregiver reportedly voiced their concerns to the patient's provider but was not satisfied with the provider's response to her concerns.The caregiver stated that the patient has had depression since she was 16 and has been drinking alcohol from "an early age".Per the caregiver, the patient entered rehab for her alcohol use disorder earlier in 2023 and since leaving rehab her depression has gotten worse.Neuronetics contacted the patient's provider for further information.Per the provider, the patient began to reportedly experience her symptoms following her course of tms.Provider noted that patient did experience headaches during tms but they reportedly had gotten worse following tms.The provider noted that these symptoms were of an unclear etiology and "would be unusual for tms to cause symptoms after tms completed".The provider reported that the patient discontinued her viibryd during treatment herself which could have resulted in the patient experiencing a "serotonin withdrawal" but the caregiver states that the patient did not have any medication changes during treatment.The provider recommended that the patient see a neurologist but at this time the patient has not had a chance to see one.Based on the confounding information provided, it cannot be determined whether the tms treatment caused or contributed to the patient's condition.The company is reporting out of an abundance of caution.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
NEUROSTAR ADVANCED THERAPY
Type of Device
TRANSCRANIAL MAGNETIC STIMULATOR
Manufacturer (Section D)
NEURONETICS, INC.
3222 phoenixville pike
malvern PA 19355
Manufacturer (Section G)
NEURONETICS, INC.
3222 phoenixville pike
malvern PA 19355
Manufacturer Contact
anna gorbunov
3222 phoenixville pike
malvern, PA 19355
6106404202
MDR Report Key18836091
MDR Text Key336866503
Report Number3004824012-2024-00005
Device Sequence Number1
Product Code OBP
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K083538
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Consumer
Reporter Occupation Non-Healthcare Professional
Type of Report Initial
Report Date 03/05/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/05/2024
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberNEUROSTAR ADVANCED THERAPY V1.0
Device Catalogue Number81-60000-000
Was Device Available for Evaluation? No
Date Manufacturer Received02/05/2024
Was Device Evaluated by Manufacturer? No
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Unknown
Patient Sequence Number1
Treatment
ACAMPROSATE 666 MG TID; BUPROPRION 150 MG QD; GABAPENTIN 600 MG BID; VIIBRYD 40 MG QD
Patient Outcome(s) Other;
Patient Age47 YR
Patient SexFemale
Patient Weight81 KG
Patient RaceWhite
-
-